Cargando…

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019

Objective: To compare Anti-Xa directed thromboprophylaxis using low molecular weight heparin (LMWH) (anti-Xa peak goal 0.2-0.5 IU/mL) to alternative anticoagulation strategies in critically ill COVID-19 patients. Methods: This was a retrospective, multicenter, single health-system study. Primary out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Adham, Shemanski, Shelby M, Saad, Mohamed O, Ploetz, Jeannette, Haines, Michelle M, Schlachter, Andrew B, Hamarshi, Majdi S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358597/ https://www.ncbi.nlm.nih.gov/pubmed/35924413 http://dx.doi.org/10.1177/10760296221116350

Ejemplares similares

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved?
por: Stanciakova, Lucia, et al.
Publicado: (2022)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Adequate thromboprophylaxis in critically ill patients
por: Levi, Marcel
Publicado: (2010)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Thromboprophylaxis for medical inpatients with coronavirus disease 2019
por: Dalager-Pedersen, M., et al.
Publicado: (2020)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis
por: Manoharan, Arumugam, et al.
Publicado: (2022)

Beyond the ventilator: Rehabilitation for critically ill patients with coronavirus disease 2019
por: Tan, Sing Chee, et al.
Publicado: (2020)

Coronavirus disease 2019 in pregnancy: consider thromboembolic disorders and thromboprophylaxis
por: Di Renzo, Gian Carlo, et al.
Publicado: (2020)

Pulmonary thromboembolism in coronavirus disease 2019 patients undergoing thromboprophylaxis
por: Schiaffino, Simone, et al.
Publicado: (2021)

Hyperoxia is associated with a greater risk for mortality in critically ill traumatic brain injury patients than in critically ill trauma patients without brain injury
por: Douin, David J, et al.
Publicado: (2023)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Anxiety and fear related to coronavirus disease 2019 assessment in the Spanish population: A cross-sectional study
por: Allande-Cussó, Regina, et al.
Publicado: (2021)

Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study
por: Al Harbi, Shmeylan, et al.
Publicado: (2022)

Lymphocytes, Mean Platelet Volume, and Albumin in Critically Ill COVID-19 Patients with Venous Thromboembolism
por: Duan, Rundan, et al.
Publicado: (2023)

Application of a flexible visitation system in critically ill patients: A randomized clinical trial
por: Yang, Hu-yong, et al.
Publicado: (2023)

Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
por: Lauzier, François, et al.
Publicado: (2014)

Financialisation, regional economic development and the coronavirus crisis: a time for spatial monetary policy?
por: Sokol, Martin, et al.
Publicado: (2021)

A Case Report of Home-Based Cognitive-Behavioural Treatment for Late-Onset Post-Traumatic Stress Disorder, Triggered by Mask-Wearing in the Context of the COVID-19 Pandemic
por: Hanafi, Adham
Publicado: (2022)

Appropriateness of Using Vitamin K for the Correction of INR Elevation Secondary to Hepatic Disease in Critically ill Patients: An Observational Study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Doxycycline’s Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study
por: Al Sulaiman, Khalid, et al.
Publicado: (2023)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
por: Ferrandis, Raquel, et al.
Publicado: (2020)

Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Carboxyhemoglobinemia in Critically Ill Coronavirus Disease 2019 Patients
por: Faisal, Hina, et al.
Publicado: (2021)

What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?
por: Cauchie, Philippe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lhabbc5ktmcaqd7k0m19gk3389